



## **BACKGROUND/REASON FOR SUPPLEMENT**

The 180-day PMA/S (subject file) was submitted by Medtronic Inc. (the company) for requesting the approval of the MyCareLink Patient Monitor Models 24950, 24951, 24955 for the above devices. The PMA/S (the subject file) contains the Telemetry C communication and the software modifications.

MyCareLink Patient Monitor, Models 24950 and 24951, have been designed as the replacements for the current monitors (Medtronic CareLink Monitors such as the Models 2490G, 2490H, and 2490C), it also including the MLink cellular adapter, by merging the functionality in order to simplify the design and improve the user experience.

## **INDICATIONS FOR USE**

NOTE: The company claims, “the indications for use” are unaffected by the proposed changes in this PMA/S.

## **DEVICE DESCRIPTIONS**

MyCareLink is a patient monitor used by patients to remotely transmit implantable device data to the CareLink Network for their clinic to view. Communication with the implanted device (interrogation) is achieved through Radio-Frequency (RF) telemetry. Communication to the CareLink Network is achieved through cellular connectivity, or through an optional analog telephone line connection. The subject file is for the Telemetry C only.


## **THE SUMMARY FOR THE REVIEW**

MyCareLink is a patient monitor used by patients to remotely transmit implantable device data to the CareLink Network for their clinic to view. Communication with the implanted device (interrogation) is achieved through Radio-Frequency (RF) telemetry. Communication to the CareLink Network is achieved through cellular connectivity, or through an optional analog telephone line connection.

The intended use for MyCareLink remains as currently approved for the 2490G/H/C monitors. Although new labeling has been created to reflect the new user experience, contraindications, and relevant warnings and precautions remain the same. MyCareLink is intended for global use, and the labeling has been modified based on the comments from FDA.

MyCareLink was developed and tested in accordance with the Medtronic procedures, and underwent non-clinical bench testing, which included verification testing and system validation testing. Verification testing was conducted on the various subsystems of MyCareLink to establish that the subsystems meet their defined specifications. MyCareLink completed all verification testing. System validation testing was conducted against the overall product requirements specifications, and to assess reliability of the system as it would be used in its intended environment. The reliability of the system was assessed by operating and stressing the system, as it would perform in its intended environment. Typical user scenarios performed during a device interrogation and transmission session were conducted. In addition, the system validation testing stressed the system to assure its specified operation when exercised with unexpected user scenarios. System validation testing also assured operation per its labeling. MyCareLink completed all system validation testing. After FDA reviewed the test reports in the subject PMA/S file, FDA provided the comments to the company, and the company has fully addressed the comments from FDA. Based on the responses from the company, all the testing of the subject device is acceptable.

The follow figure is a general fig. for the system, the subject PMA/S contains the Telemetry C only.



**BIOCOMPATIBILITY:** N/A

**ANIMAL STUDY:** N/A

**CLINICAL DATA:** N/A

**LABELING:**

The labeling for the subject device is provided in the file, the final drafted version of the labeling in the subject PMA/S is acceptable with the comments from FDA.

**CONCLUSION**

It is recommended, the approval for the subject file.